

National Blood Sector Research and Development Pilot



Frequently Asked Questions

5 April, 2016

Q1. In section 2 the following is requested:

“Confirm that letters of support for this research project have been obtained from all participating institutions named in this application above. Provide a copy of each letter with your application. If you are unable to provide a copy of any letter of support please provide reasons for this.”

If the study has been approved by Ethics (which included signatures of all participating members/units) would a copy of this be sufficient or are individual letters essential?

Answer: Signed ethics approval is not sufficient. Letters from all participating institutions named in the application must be provided. These institutions should acknowledge the support that they are expected to provide within the application.

Q2. Will my specific research topic be suitable?

Answer: The NBA is not pre-screening applications to provide advice on whether or not a specific topic is suitable. The decision to apply or not must be made by the applicant.

Applicants should ensure that their topic is listed as an evidence gap in the PBM Guidelines OR listed as a high priority topic within the Immunoglobulin stream. These topics are listed on page 2 of the Information for Applicants Booklet.

The application should also meet the eligibility requirements outlined on Page 5 of the Information for Applicants Booklet.

Q3. Are there budget limits for each grant type?

Answer: An indicative amount for each grant type is listed on page 3 of the Information for Applicants booklet. The total funding allocated to R&D Pilot is \$2.4M (\$1.2M per round). This translates to \$400,000 per year for both grant streams (PBM and Immunoglobulin) and all grant types (Project Grants, Seed Grants and Early Career Research Grants). The number of grants to be awarded for each stream and grant type depends on the number and quality of applications received.

Q4. Where the application form stipulates confirmation that essential partners and stakeholders named in this application have agreed to be named within the application and have endorsed the application, is written evidence of such confirmation required?

Answer: No. There is no requirement to provide evidence. This is a tick-box answer. However, if you cannot answer “Yes” then you must provide the reasons that the essential partners or stakeholders named in the application have not agreed to be named or have not endorsed the application.

Q5. Is written confirmation required from CIs, AIs and other research team members named in the application?

Answer: No. There is no requirement to provide evidence. This is a tick box answer. However, if you cannot answer “Yes” then you must provide the reasons that the CIs, AIs or other research team members have not agreed to be named in the application.

Q6. Are completed and signed conflict of interest forms required as a part of the initial application?

Answer: A conflict of interest form is not required as a part of your initial application due on 8/03/2016. Conflict of interest forms will be required before finalisation of funding agreements with successful applicants.

Q7. Where can I find the Evidence Gaps for PBM Guidelines Module 6?

Answer: They are available upon request by emailing R&D@blood.gov.au.

Q8. Do you want bio's for the Chief Investigator(s) even if they are not being funded?

Answer: While bios for non-funded team members are not required for Round 1, they would be appreciated if provided. Bio's for CI's will be required in Round 2.

